Issue 3/2011

Expression of soluble TGF-β receptor II by recombinant Vaccinia virus enhances E7 specific immunotherapy of HPV16 tumors (181 — 188)

K. ZURKOVA, P. CHLANDA, Z. SAMKOVA, K. BABIAROVA, L. KUTINOVA, J. KRYSTOFOVA, P. HAINZ, S. NEMECKOVA

DOI: 10.4149/neo_2011_03_181

Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. (189 — 197)

Z. SLOBODOVA, J. EHRMANN, V. KREJCI, J. ZAPLETALOVA, B. MELICHAR

DOI: 10.4149/neo_2011_03_189

BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer (198 — 204)

M. CVELBAR, M. HOCEVAR, G. VIDMAR, E. TEUGELS

DOI: 10.4149/neo_2011_03_198

Down-regulation of iASPP in human hepatocellular carcinoma cells inhibits cell proliferation and tumor growth (205 — 210)

B. L. LIN, D. Y. XIE, S. B. XIE, J. Q. XIE, X. H. ZHANG, Y. F. ZHANG, Z. L. GAO

DOI: 10.4149/neo_2011_03_205

Overexpression of B cell-activating factor (BAFF) in neutrophils of oral cavity cancer patients – preliminary study (211 — 216)

E. JABLONSKA, B. SLODCZYK, N. WAWRUSIEWICZ-KURYLONEK, M. GARLEY, D. DZIEMIANCZYK, A. KRETOWSKI, S. Z. GRABOWSKA

DOI: 10.4149/neo_2011_03_211

Identification of site-specific prognostic biomarkers in patients with oral squamous cell carcinoma (217 — 226)

T. I. TRIVEDI, R. A. TANKSHALI, J. V. GOSWAMI, S. N. SHUKLA, P. M. SHAH, N. G. SHAH

DOI: 10.4149/neo_2011_03_217

Camptothecin-induced death of amelanotic and melanotic melanoma cells in different phases of cell cycle (227 — 234)

M. CICHOREK

DOI: 10.4149/neo_2011_03_227

D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C – role in prothrombotic state of colorectal cancer. (235 — 238)

M. MYTNIK, J. STASKO

DOI: 10.4149/neo_2011_03_235

Wnt/β-catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells (239 — 244)

X. H. WANG, X. W. MENG, X. SUN, B. R. LIU, M. Z. HAN, Y. J. DU, Y. Y. SONG, W. XU

DOI: 10.4149/neo_2011_03_239

Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer (245 — 250)

Y. S. KIM, S. J. KIM, Y. K. KIM, I. J. KIM, Y. D. KIM, M. K. LEE

DOI: 10.4149/neo_2011_03_245

Association of Toll like receptor 9 expression with lymph node metastasis in human breast cancer (251 — 255)

J. QIU, S. SHAO, G. YANG, Z. SHEN, Y. ZHANG

DOI: 10.4149/neo_2011_03_251

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia (256 — 262)

J. VOGLOVA, J. MUZIK, E. FABER, D. ZACKOVA, H. KLAMOVA, K. STEINEROVA, Z. MICHALOVICOVA, L. DEMITROVICOVA, E. CMUNT, L. NOVAKOVA, E. TOTHOVA, P. BELOHLAVKOVA, J. MAYER, K. INDRAK

DOI: 10.4149/neo_2011_03_256

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy (263 — 270)

V. PROCHAZKA, T. PAPAJIK, J. GAZDOVA, M. DIVOKA, S. ROZMANOVA, E. FABER, L. RAIDA, L. KUCEROVA, K. LANGOVA, M. JAROSOVA, K. INDRAK

DOI: 10.4149/neo_2011_03_263